MapLight Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
MapLight Therapeutics, Inc. (MPLT) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$5.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.85M, a 142.65% decline year-over-year.
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$2.48M, a 1382.38% decline year-over-year.
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.33M, a 66.95% increase year-over-year.
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $3.91M.
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $13.10M, a 475.45% increase from fiscal 2024.
- MapLight Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.28M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.32M 10-Q · filed 2026-08-13 | -$2.99M derived: sum of 3 quarters · filed 2026-08-13 | $916.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.48M 10-Q · filed 2026-05-14 | -$146.00K derived: sum of 2 quarters · filed 2026-05-14 | $3.76M derived: sum of 3 quarters · filed 2026-05-14 | $10.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $6.24M derived: sum of 2 quarters · filed 2026-03-26 | $12.91M derived: sum of 3 quarters · filed 2026-08-13 | $13.10M 10-K · filed 2026-03-26 |
| 2025-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | $10.58M derived: sum of 2 quarters · filed 2026-08-13 | $10.77M 10-Q · filed 2025-12-04 | $12.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.87M 10-Q · filed 2026-08-13 | $8.26M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $193.00K 10-Q · filed 2026-05-14 | $1.59M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.28M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $882.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |